Advertisement

Topics

Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

10:00 EDT 18 Sep 2018 | Investing News Network

Canntab Therapeutics (CSE:PILL) ("Canntab" or the "Company"), today announced the achievement of a milestone with regards to the development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV: EMC) (OTCQX: EMMBF), a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") through its wholly-owned subsidiary Emblem Cannabis Corporation (collectively, "Emblem").

The post Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials appeared first on Investing News Network.

Original Article: Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials

NEXT ARTICLE

More From BioPortfolio on "Canntab and Emblem Announce Positive Results on Testing: Proceeding to Clinical Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...